Ocular Neoplastic Diseases

Ocular neoplastic diseases refer to the development of tumors or cancerous growths within the eye and surrounding ocular structures. As a provider of research services, Protheragen offers comprehensive drug and therapy development services tailored to ocular neoplastic diseases.

Introduction to Ocular Neoplastic Diseases

Ocular neoplastic diseases refer to a range of tumors that develop in the eye, which can be either benign or malignant. These tumors can arise from various tissues within the eye, including the retina, uvea (which consists of the iris, ciliary body, and choroid), and the optic nerve. The pathogenesis of these tumors often involves genetic mutations, environmental factors, and, in some cases, hereditary predispositions. Ocular neoplasms can lead to significant visual impairment and may result in systemic complications if left untreated. The most common malignant ocular tumors include retinoblastoma in children and uveal melanoma in adults.

Fig.1 Photomicrographs of the same tissue illustrating the IHC staining pattern of a complex tumor of the gland of the third eyelid. (A) Cytokeratin, (B) vimentin, (C) SMA. (Dubielzig R. R., et al., 2016)

Current Status of Ocular Neoplastic Disease Therapy Development

The landscape of drug and therapy development for ocular neoplastic diseases is rapidly evolving, driven by advances in molecular biology and a better understanding of tumor biology.

• Targeted Therapies
  Targeted therapies focus on precision by targeting specific molecular pathways linked to tumor proliferation and survival. In the realm of uveal melanoma, ongoing research is dedicated to formulating inhibitors that specifically target the mitogen-activated protein kinase (MAPK) pathway, frequently activated in these tumors. Promising clinical trials are underway to assess the effectiveness of these targeted agents when combined with conventional treatment modalities.
• Immunotherapy
  Immunotherapy has emerged as a promising avenue for treating a wide range of cancers, including ocular neoplasms. Immune checkpoint inhibitors like pembrolizumab and nivolumab are under scrutiny for their ability to bolster the body's immune response against malignant cells. Initial research has displayed promising outcomes in individuals with metastatic uveal melanoma.

Table 1. Clinical trials registered on clinicaltrials.gov for different ocular neoplastic diseases. (Niu Y., et al., 2024)

Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Ocular neoplastic diseases represent a significant challenge in the field of ophthalmology, but Protheragen's unwavering commitment to innovation and excellence in drug and therapy development is driving meaningful progress. By combining cutting-edge science and expertise, our company provides customized solutions to pharmaceutical companies around the world.

Types of Ocular Neoplastic Diseases

Our Therapeutics Development Solutions

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein

Preclinical Research

• Pharmacodynamics Study Services
• Pharmacokinetics Study Services
• Drug Safety Evaluation Services

Disease Models

• Cell-based Models Development Service
• Organoid Models Development Service
• Animal Models Development Services

Protheragen conducts rigorous preclinical studies to evaluate the safety and efficacy of new therapeutic agents. This includes in vitro and in vivo models to assess drug activity and pharmacokinetics. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

• Dubielzig, Richard R. "Tumors of the eye." Tumors in domestic animals (2016): 892-922.
• Niu, Yifei, et al. "Regenerative treatment of ophthalmic diseases with stem cells: Principles, progress, and challenges." Advances in Ophthalmology Practice and Research (2024).